• AAPL 169.105
  • TSLA 166.955
  • AMZN 172.3532
  • MSFT 396.35
  • INTC 34.975
  • EURUSD 1.0734
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. COYA.NASDAQ

Coya Therapeutics Inc. Common Stock (COYA NASDAQ) stock market data APIs

$8.05 -0.36(-4.3%) as of April 24, 2024

Coya Therapeutics Inc. Common Stock Financial Data Overview

8.41
8.05
-
9.22
8.05
3.21-10.6899
124 M
14 602 K
6 002 K
0.28
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'COYA',
Type: 'Common Stock',
Name: 'Coya Therapeutics Inc. Common Stock',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
ISIN: NULL,
CUSIP: NULL,
CIK: '1835022',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2022-12-29',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Coya Therapeutics Inc. Common Stock Fundamental Data is available in our Financial Data APIs

  • Net Revenue 6 002 K
  • EBITDA -7 332 802
  • Earnings Per Share -0.79
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Coya Therapeutics Inc. Common Stock Earnings via APIs

  • Latest Release 2024-03-19
  • EPS/Forecast 0.26

Get Coya Therapeutics Inc. Common Stock End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Coya Therapeutics Inc. Common Stock latest news via APIs

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets. Pipeline programs in Small Cell Lung Cancer a...

Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Under the Agreement, Dr. Reddy’s will obtain commercialization rights for COYA 302 in the United States, Canada, the European Union and the United Kingdom, for patients with ALS COYA will be respon...
Do you have any questions?
support@eodhistoricaldata.com